S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:PRQR

ProQR Therapeutics (PRQR) Stock Forecast, Price & News

$1.47
-0.01 (-0.68%)
(As of 09/22/2023 ET)
Compare
Today's Range
$1.47
$1.50
50-Day Range
$1.36
$1.77
52-Week Range
$0.72
$3.85
Volume
90,293 shs
Average Volume
130,959 shs
Market Capitalization
$118.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.88

ProQR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
164.2% Upside
$3.88 Price Target
Short Interest
Healthy
1.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.56mentions of ProQR Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.25) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

841st out of 963 stocks

Pharmaceutical Preparations Industry

407th out of 455 stocks


PRQR stock logo

About ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

PRQR Price History

PRQR Stock News Headlines

ProQR Therapeutics (NASDAQ:PRQR) PT Lowered to $1.80
ProQR Therapeutics (NASDAQ:PRQR) Lowered to Hold at StockNews.com
Wall Street Legend Warns "Mass Bank Run" is Coming
Man who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
4 Analysts Have This to Say About ProQR Therapeutics
Wall Street Legend Warns "Mass Bank Run" is Coming
Man who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
PRQR Oct 2023 7.500 call
2 Biotech Stocks to Buy, 1 to Sell Now
Chardan Capital Remains a Hold on ProQR (PRQR)
H.C. Wainwright Sticks to Its Buy Rating for ProQR (PRQR)
Positive Report for ProQR (PRQR) from JMP Securities
See More Headlines
Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRQR
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.88
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$1.80
Forecasted Upside/Downside
+164.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-68,600,000.00
Net Margins
-1,427.27%
Pretax Margin
-1,433.16%

Debt

Sales & Book Value

Annual Sales
$4.25 million
Book Value
$0.85 per share

Miscellaneous

Free Float
74,028,000
Market Cap
$118.81 million
Optionable
Optionable
Beta
-0.02
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Domenico Valerio Ph.D. (Age 67)
    Founder & Independent Chairman of Supervisory Board
    Comp: $79.35k
  • Mr. Daniel Anton de Boer (Age 40)
    Founder, CEO & Member of Management Board
    Comp: $1.41M
  • Mr. Rene K. Beukema (Age 59)
    Chief Corp. Devel. Officer, Gen. Counsel & Member of Management Board
    Comp: $315.27k
  • Dr. Gerard Platenburg (Age 59)
    Co-Founder & Chief Scientific Officer
  • Mr. Jurriaan Dekkers (Age 47)
    Chief Financial Officer
  • Ms. Sheila Sponselee (Age 39)
    VP & Head of People and Operations
  • Ms. Sarah Cue Kiely
    VP of Investor Relations & Corp. Communications
  • Ms. Sandra van der Kolk
    Jr. Financial Controller













PRQR Stock - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PRQR shares.
View PRQR analyst ratings
or view top-rated stocks.

What is ProQR Therapeutics' stock price forecast for 2023?

6 Wall Street research analysts have issued 12-month price targets for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $1.80 to $5.00. On average, they predict the company's share price to reach $3.88 in the next year. This suggests a possible upside of 164.2% from the stock's current price.
View analysts price targets for PRQR
or view top-rated stocks among Wall Street analysts.

How have PRQR shares performed in 2023?

ProQR Therapeutics' stock was trading at $3.70 at the beginning of the year. Since then, PRQR shares have decreased by 60.3% and is now trading at $1.47.
View the best growth stocks for 2023 here
.

When is ProQR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our PRQR earnings forecast
.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) issued its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. The biopharmaceutical company had revenue of $1.31 million for the quarter, compared to analyst estimates of $2.77 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 86.23% and a negative net margin of 1,427.27%.

What ETF holds ProQR Therapeutics' stock ?

Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Marshall Wace LLP (0.38%), Monaco Asset Management SAM (0.29%), Renaissance Technologies LLC (0.25%), JPMorgan Chase & Co. (0.22%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of ProQR Therapeutics?

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $1.47.

How much money does ProQR Therapeutics make?

ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $118.81 million and generates $4.25 million in revenue each year. The biopharmaceutical company earns $-68,600,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

The company employs 130 workers across the globe.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.

This page (NASDAQ:PRQR) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -